Kevin S Tang

Dr. Kevin S Tang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2020 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
KTKevin S Tang
Kevin S Tang
EMEdward D. Medeiros
Edward D. Medeiros
ASAnkur Shah
Ankur Shah
Pulse pressure naturally increases over time as individuals’ age due to arteriosclerosis and diffuse vascular stiffening. However, the differential for widened pulse pressure is broad and includes causes of hyperdynamic circulation and high‐output heart failure, such as aortic regurgitation and hyperthyroidism. In the absence of an underlying cause, wide pulse pressure is a sign of deteriorating cardiovascular health and carries increased risk for mortality, disease progression, and adverse clinical outcomes in chronic diseases including cardiovascular disease and chronic kidney disease. Current emphasis of antihypertensive treatment on systolic and diastolic blood pressure does not always address pulse pressure, thus subjecting many patients to an independent risk factor for poor outcomes. Pulse pressure control is more successfully achieved with thiazide diuretics and long‐acting nitrates when compared to other antihypertensive agents, but further research is needed to quantify the additional benefits of pulse pressure control over conventional blood pressure therapy. This case review provides an overview of the pathogenesis, pathologic causes, and treatment of widened pulse pressure and evaluates current evidence for pulse pressure as a predictor of clinical outcomes.

30 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JJJeffrey E Jones
Jeffrey E Jones
KTKevin S Tang
Kevin S Tang
AEAilin Barseghian El-Farra
Ailin Barseghian El-Farra
Nathan D. WongNathan D. Wong
Nathan D. Wong
Over the last half-century, discussions on the exact targets for low-density lipoprotein cholesterol (LDL-C) reduction have evolved towards a more aggressive approach with lower LDL-C targets, particularly for high-risk patients with pre-existing atherosclerotic cardiovascular disease (ASCVD). A wealth of cardiovascular outcome trials have shown the efficacy of statin therapy in general, as well as the incremental impact of high-intensity statin therapy in particular. More recent trials have further demonstrated the impact of non-statin therapies, including ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and, most recently, bempedoic acid, on reducing ASCVD outcomes. The availability of these and other newer therapies has prompted clinicians to strive for lower LDL-C targets to address residual ASCVD risk after statin therapy. This paper will provide an overview of the historical trends in lipid management and therapeutics and review the current state of evidence for lower LDL-C targets in clinical guidelines and recommendations.

11 December 2023 in Interventional Cardiology: Reviews, Research, Resources
Verified
Journal Article
Open access
PDF file
KTKevin S Tang
Kevin S Tang
SBShoujit Banerjee
Shoujit Banerjee
GTGeorge Tang
George Tang
PPPranav M Patel
Pranav M Patel
AFAntonio H Frangieh
Antonio H Frangieh
Percutaneous coronary intervention with stent implantation is an integral aspect of minimally interventional cardiac procedures. The technology and techniques behind stent design and implantation have evolved rapidly over several decades. However, continued discourse remains around optimal peri- and post-interventional management with dual antiplatelet therapy to minimise both major cardiovascular or cerebrovascular events and iatrogenic bleeding risk. Standard guidelines around dual antiplatelet therapy historically recommended long-term dual antiplatelet therapy for 12 months (with consideration for >12 months in certain patients); however, emerging data and generational improvements in the safety of drug-eluting stents have ushered in a new era of short-term therapy to reduce the incidence of major bleeding events. This case review will provide an overview of the current state of guidelines around duration of dual antiplatelet therapy and examine recent updates and continued gaps in existing research.

9 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SFSaam Foroshani
Saam Foroshani
KTKevin S Tang
Kevin S Tang
Nathan D. WongNathan D. Wong
Nathan D. Wong
Frailty is a multidimensional state of reduced physiological reserve that is increasingly recognized as a major determinant of outcomes in cardiovascular diseases (CVDs). As populations age and cardiometabolic multimorbidity becomes more prevalent, understanding how frailty interacts with CVD pathology has important implications for risk stratification, clinical decision-making, and patient-centered care. Across diverse cardiovascular conditions and interventions, frailty independently predicts higher risks of mortality, major adverse cardiovascular events (MACE), rehospitalization, procedural complications, functional decline, and reduced quality of life. Shared biological mechanisms—including chronic inflammation, sarcopenia, endothelial dysfunction, and the effects of multimorbidity and polypharmacy—help explain the strong and often bidirectional relationship between frailty and CVD, one that is reported by recent data to be multiplicative as well as additive. Importantly, frailty demonstrates prognostic value beyond traditional risk factors and varies in predictive performance depending on the assessment tool used. Finally, frailty should not be viewed as immutable; evidence shows that appropriate conditioning may slow the decline or even reverse frail or prefrail states. This narrative review aims to synthesize contemporary evidence on frailty definitions and assessment, epidemiology, mechanistic pathways linking frailty with CVD, associated outcomes, prognostic value, and emerging interventions relevant to CVD prevention and management.

2 September 2025 in JACC: Asia
Verified
Journal Article
Open access
KTKevin S Tang
Kevin S Tang
WFWenjun Fan
Wenjun Fan

1 February 2025 in American Journal of Hypertension
Verified
Journal Article
Closed access
KTKevin S Tang
Kevin S Tang
JJJeffrey E Jones
Jeffrey E Jones
WFWenjun Fan
Wenjun Fan
Nathan D. WongNathan D. Wong
Nathan D. Wong
BACKGROUND: Hypertension (HTN) has been demonstrated as one of the leading risk factors for development of cardiovascular disease (CVD) and CVD mortality. METHODS: This study examines the prevalence and distribution of HTN subtypes (isolated diastolic hypertension [IDH], isolated systolic hypertension [ISH], and systolic-diastolic hypertension [SDH]) across age, sex, and race/ethnicity per the nationally representative National Health and Nutrition Examination Survey (NHANES) from 1999 to 2020 based on the updated 2017 ACC/AHA HTN definition. We further examined for associations of each subtype with CVD and all-cause mortality using Cox regression analysis. RESULTS: Among US adults, the overall prevalence of HTN is 47.4%. Across increasing age, the prevalence of IDH decreased, ISH increased, and SDH increased and peaked in the 6th decade of life after which SDH prevalence decreased. By age 80, over 80% of persons with HTN demonstrated ISH. A subcohort from NHANES 1999–2008 with follow-up until 2018 showed that ISH and SDH were most strongly associated with increased risk for CVD (HR = 1.18, 95% CI, 1.01–1.38; HR = 1.31, 95% CI, 1.07–1.60, respectively) and all-cause mortality (HR = 1.17, 95% CI, 1.06–1.28; HR = 1.21, 95% CI, 1.08–1.37, respectively). CONCLUSIONS: Our data demonstrate the continuing importance of HTN subtype transitions across age and their differences in predicting future CVD and total mortality.